title: [Side effects of erectile dysfunction drug treatment].
abstract: Due to the large number of drugs now available, the therapy of erectile dysfunction has changed profoundly in recent decades. The phosphodiesterase type 5 inhibitors (PDE5-i): sildenafil, taldalafil, vardenafil, and avanafil are EMA European Medicines Agency approved and show similar adverse events and success rates. The absolute contraindication is the simultaneous use of nitrates. Despite this wide variety of options, therapy of erectile dysfunction should be performed in an individually adapted manner. The exact patient's history, physical examination, collaboration of medical disciplines, and choice of therapy will offer every patient the possibility to achieve or regain a satisfying sexual life.
authors.affiliation: Urologische Klinik, Kliniken Maria Hilf GmbH, Viersener Str. 450, 41063, Mönchengladbach, Deutschland. herbert.sperling@mariahilf.de.
authors.forename: H
authors.initials: H
authors.lastname: Sperling
mesh_terms: D000075203:Contraindications, Drug; D004359:Drug Therapy, Combination / Q000009:adverse effects; D007172:Erectile Dysfunction / Q000150:complications* / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D008297:Male; D009566:Nitrates / Q000009:adverse effects*; D058986:Phosphodiesterase 5 Inhibitors / Q000009:adverse effects*; D012307:Risk Factors; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000009:adverse effects; D014665:Vasodilator Agents / Q000009:adverse effects*
chemical_list: D009566:Nitrates; D058986:Phosphodiesterase 5 Inhibitors; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents
keywords: Combination therapy; Hypersensitivity; Mechanism of action; Monotherapy; Pharmacology